TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6
Saturday, June 17, 2023
TG ImmunoPharma announced the FDA clearance for the clinical trial of TGI-6. This antibody is designed to target unique tumour-associated antigens (TAA) and CD3 molecules, resulting in effective antitumor responses.
TGI-6 has demonstrated exceptional anti-tumour activity and possesses favourable safety profiles, along with remarkable druggability. The TAA (Tumour-Associated Antigen) targeted by TGI-6, is known to be highly expressed in several solid tumours. These tumours include colourectal cancer, breast cancer, hepatocellular carcinoma (liver cancer), gastric cancer, ovarian cancer, pancreatic cancer, and potentially other types as well.
TGI-6 is designed to maintain high cytotoxic activity against cancer cells while minimising the risk of cytokine release syndrome (CRS), a potentially harmful immune response. This feature enhances the safety and therapeutic potential of TGI-6.
TGI remains steadfast in its mission to transform cancer care through innovative immunotherapies. The FDA's approval of the TGI-6 clinical trial is expected to propel the progress of precision therapies for solid tumours.
